Big Money in Swine Flu Stocks

Today was a good day for Swine flu stocks. Most small caps were up 5 to 10% today alone. So lets go over today's Swine Flu winners. Many investor's still think this is a lot of hype but with Flu season coming around the corner, I see things only getting worse. I have been a Microbiologist by trade and do see this as an outbreak, maybe not a pandemic, but anything is possible. The US government is spending Billions on getting vaccines ready for Flu Season. I am only including the small caps here but Novartis, Glaxo, Baxter, Roche and Gilead are the big players in the market.

BioCryst Pharmaceuticals (BCRX) 12.60 +2.55 up 25.37%
Hemispherx Biopharma (HEB) 2.22 +0.32 up 16.84%
Sinovac Biotech Ltd. (SVA) 5.47 +0.54 up 10.95%
Novavax, Inc. (NVAX) 5.21 +0.45 up 9.45%
CEL-SCI Corp. (CVM) 0.475 +0.0273 up 6.10%


All this is based on a report out from the President's Panel earlier today. The Washington Post article is titled Swine Flu Could Infect Half of U.S. Population, Report Says. Understood is the fact that no one can predict how good or bad the Flu season will be, but I see it above average at minimum. Most schools and colleges are starting back in the next couple of weeks if not already and anyone with kids knows how easy germs spread with children. Colleges are just the same. Colleges can be breeding grounds for these outbreaks to occur.

Most of these profits are on hype and you should take caution with investments based on volatility alone. However, I see these as strong buys coming into flu season. Wait for them to come down just a bit before investing with a limit order at a set price. As always, do your homework and check the companies financial information before investing.

Doing some research on the H1N1 outbreak here are some good links.

CDC's 2009 H1N1 Flu (Swine Flu)

CDC's Weekly Flu View

Google News Search Swine Flu

CNN Swine Flu Goes To College

Google News Search H1N1

Southern Hemisphere's swine flu experience holds hints of what may be ahead

HEB down after Heavy Trading and July 22 Call

TheStreet posted today the following article concerning Hemispherx Biopharma. Still I think this is a good trade but with news about Human Genome the Biotech Industry is under huge pressure to reach expectations and everyone's looking for a quick buck. Hold onto those investments people. The market fluctuates, you just have to ride it out sometimes. But many buy and sell on the Clinical Trial news and I can't blame them. However, I still say Long on HEB. I like companies that have more than one option in their pipeline. Anyways, shares plunged today and I say its still a good buy. Invest with caution as anything can happen. Diversify and spread your stocks out so you don't loose everything is things go sour. Here's the news on HEB today.




Updates on Hemispherx Conference Call Fail to Sooth Investors (HEB)

Selling in shares of Hemispherx BioPharma (AMEX: HEB) has intensified since 10am ET, when the company began a teleconference to provide updates on its recent Influenza research initiatives. After opening today's trading session down about 5%, the stock has now fallen more than 27%, most recently trading at $2.43. Notably, Hemispherx shares are seeing extremely heavy volume today, already trading nearly 26 million times, which compares to the stock's average daily volume of just 7 million shares.

Before this morning's decline, shares of Hemispherx jumped more than 55% since the beginning of this week, when the company first announced that it would be holding today's call.

On the call, Hemispherx said it is target 25-50 million doses of Ampligen per year, as well as at least 100 million doses of Alferon LDO at capacity, two initiatives which are expected to cost the company about $10 million. The company said that a continually mutating flu virus is the main reason for concern related to this pandemic. Hemispherx also noted that is expects to see several more complete Ampligen trials during the month of August.

Related articles by Zemanta

• Swine-Flu Update: U.K. Surge, Tamiflu Sales & Vaccine Trials (blogs.wsj.com)
• Revisiting Tamiflu (oseltamivir) (blacktriangle.org)